Development of Targeted Therapies for Breast and Highly Aggressive Cancers
Cancer is one of the top two causes of deaths in the US and the world. Cancer therapy includes standard therapies such as surgery, chemotherapy and targeted therapies, by antibody and small molecule inhibitors, and immunotherapy (i.e., check point inhibitors, CAR-T cell therapy). More recently RNA-b...
Main Author: | Bulent Ozpolat |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-02-01
|
Series: | Proceedings |
Subjects: | |
Online Access: | https://www.mdpi.com/2504-3900/40/1/48 |
Similar Items
-
ncRNA therapy with miRNA-22-3p suppresses the growth of triple-negative breast cancer
by: Aysegul Gorur, et al.
Published: (2021-03-01) -
Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer
by: María del Mar Noblejas-López, et al.
Published: (2019-08-01) -
<i>BARD1</i> Pathogenic Variants Are Associated with Triple-Negative Breast Cancer in a Spanish Hereditary Breast and Ovarian Cancer Cohort
by: Paula Rofes, et al.
Published: (2021-01-01) -
Associations of pathogenic mutations responsible for breast cancer risk with histology and immunohistochemistry in Romanian population
by: Goidescu Iulian Gabriel, et al.
Published: (2018-04-01) -
A clinicopathologic study of triple negative breast cancer
by: Vandana L Gaopande, et al.
Published: (2015-01-01)